DISEASE INDICATIONS: Leukemia

MANUFACTURER: Novartis Europharm Limited

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Therapeutic Goods Administration (TGA)

Medsafe (NZ)

Rydapt (midostaurin) is prescribed to treat newly diagnosed acute myeloid leukemia (AML), aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL) in patients.